William Hoffman Sells 1,451 Shares of Inari Medical, Inc. (NASDAQ:NARI) Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 1,451 shares of the stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $40.00, for a total value of $58,040.00. Following the sale, the director now owns 999,782 shares of the company’s stock, valued at approximately $39,991,280. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

William Hoffman also recently made the following trade(s):

• On Monday, March 18th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $41.13, for a total value of $1,645,200.00.

Inari Medical Trading Down 0.1 %

NASDAQ NARI opened at $38.59 on Friday. The stock has a 50-day simple moving average of $46.89 and a two-hundred day simple moving average of $55.32. Inari Medical, Inc. has a fifty-two week low of $37.92 and a fifty-two week high of $71.85.

Inari Medical (NASDAQ:NARI) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.09). The company had revenue of $132.10 million for the quarter, compared to analysts’ expectations of $131.82 million. Inari Medical had a negative net margin of 0.33% and a positive return on equity of 1.23%. The business’s quarterly revenue was up 22.5% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.11) EPS. On average, research analysts anticipate that Inari Medical, Inc. will post -0.39 earnings per share for the current year.

Hedge Funds Weigh In On Inari Medical

A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. raised its stake in shares of Inari Medical by 13.0% during the 2nd quarter. BlackRock Inc. now owns 6,385,806 shares of the company’s stock valued at $371,271,000 after buying an additional 733,738 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Inari Medical by 6.9% during the 4th quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after acquiring an additional 325,586 shares during the period. Wellington Management Group LLP grew its position in shares of Inari Medical by 46.8% during the 1st quarter. Wellington Management Group LLP now owns 4,626,607 shares of the company’s stock valued at $419,355,000 after acquiring an additional 1,475,313 shares during the period. Capital International Investors grew its position in shares of Inari Medical by 0.8% during the 1st quarter. Capital International Investors now owns 2,838,045 shares of the company’s stock valued at $257,240,000 after acquiring an additional 22,159 shares during the period. Finally, Alliancebernstein L.P. grew its position in shares of Inari Medical by 12.0% during the 2nd quarter. Alliancebernstein L.P. now owns 2,305,171 shares of the company’s stock valued at $134,023,000 after acquiring an additional 247,389 shares during the period. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Needham & Company LLC reiterated a “buy” rating and set a $72.00 price objective on shares of Inari Medical in a report on Wednesday, March 6th. Truist Financial reduced their target price on Inari Medical from $61.00 to $52.00 and set a “hold” rating for the company in a research note on Friday, March 22nd. Piper Sandler lowered Inari Medical from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $85.00 to $55.00 in a research note on Thursday, February 29th. Finally, Canaccord Genuity Group restated a “buy” rating and issued a $75.00 target price on shares of Inari Medical in a research note on Friday, April 12th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $73.71.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.